Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Scientists have developed a new CAR T-cell immunotherapy strategy that uses light to activate the immune cells specifically in cancerous regions. The approach, which worked well in mice, may ... Read more
Adding Imfinzi (durvalumab) to standard chemotherapy as the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) continues to show survival benefits sustained now for two years, ... Read more
A subset of women with recurrent or advanced endometrial cancer, whose disease progressed on or after platinum-based chemotherapy, achieved clinically meaningful responses after treatment with dostarlimab, results of a ... Read more
AstraZeneca‘s Imfinzi (durvalumab) decreases the spread of cancer to other parts of the body, explaining the enhanced survival in patients with stage 3 inoperable non-small-cell lung cancer (NSCLC), according to ... Read more
Pin It on Pinterest